Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure

Gut. 2007 Jul;56(7):982-90. doi: 10.1136/gut.2006.104372. Epub 2006 Dec 21.

Abstract

Background: Acute hepatic failure secondary to paracetamol poisoning is associated with high mortality. C-jun (NH2) terminal kinase (JNK) is a member of the mitogen-activated protein kinase family and is a key intracellular signalling molecule involved in controlling the fate of cells.

Aim: To examine the role of JNK in paracetamol-induced acute liver failure (ALF).

Methods: A previously developed mouse model of paracetamol poisoning was used to examine the role of JNK in paracetamol-induced ALF.

Results: Paracetamol-induced hepatic JNK activation both in human and murine paracetamol hepatotoxicity and in our murine model preceded the onset of hepatocyte death. JNK inhibition in vivo (using two JNK inhibitors with different mechanisms of action) markedly reduced mortality in murine paracetamol hepatotoxicity, with a significant reduction in hepatic necrosis and apoptosis. In addition, delayed administration of the JNK inhibitor was more effective than N-acetylcysteine after paracetamol poisoning in mice. JNK inhibition was not protective in acute carbon tetrachloride-mediated or anti-Fas antibody-mediated hepatic injury, suggesting specificity for the role of JNK in paracetamol hepatotoxicity. Furthermore, disruption of the JNK1 or JNK2 genes did not protect against paracetamol-induced hepatic damage. Pharmacological JNK inhibition had no effect on paracetamol metabolism, but markedly inhibited hepatic tumour necrosis foctor alpha (TNF alpha) production after paracetamol poisoning.

Conclusions: These data demonstrated a central role for JNK in the pathogenesis of paracetamol-induced liver failure, thereby identifying JNK as an important therapeutic target in the treatment of paracetamol hepatotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetaminophen / poisoning*
  • Analgesics, Non-Narcotic / poisoning*
  • Animals
  • Anthracenes / administration & dosage
  • Anthracenes / therapeutic use
  • Biopsy
  • Carbon Tetrachloride
  • Cell Death
  • Disease Models, Animal
  • Drug Administration Schedule
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use
  • Hepatocytes / enzymology
  • Hepatocytes / pathology
  • Humans
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • JNK Mitogen-Activated Protein Kinases / physiology*
  • Liver / enzymology
  • Liver Failure, Acute / chemically induced*
  • Liver Failure, Acute / drug therapy
  • Liver Failure, Acute / enzymology
  • Liver Failure, Acute / prevention & control
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Analgesics, Non-Narcotic
  • Anthracenes
  • Enzyme Inhibitors
  • Tumor Necrosis Factor-alpha
  • pyrazolanthrone
  • Acetaminophen
  • Carbon Tetrachloride
  • JNK Mitogen-Activated Protein Kinases